Industry News
ABVC BioPharma Announces Global Licensing Agreement with ForSeeCon

ABVC BioPharma, Inc. has entered into a significant global licensing agreement with ForSeeCon Eye Co...

read more
ABVC BioPharma Announces Global Licensing Agreement with ForSeeCon
March 28, 2024
Iveric Bio Awarded Permanent J-code for GA Treatment, Izervay

Iveric Bio has received permanent J-code from CMS for its GA treatment, Izervay (avacincaptad pegol ...

read more
Iveric Bio Awarded Permanent J-code for GA Treatment, Izervay
March 27, 2024
Rayner Shifts into Eco-Friendly Packaging to Reduce Carbon Footprint

Rayner announced a significant update to its packaging, marking a pivotal step towards achieving its...

read more
Rayner Shifts into Eco-Friendly Packaging to Reduce Carbon Footprint
March 26, 2024
BlueRock Therapeutics and Foundation Fighting Blindness Collaborate on IRDs Study

BlueRock Therapeutics announced a collaboration to introduce a new cohort to the Foundation's 'Uni-R...

read more
BlueRock Therapeutics and Foundation Fighting Blindness Collaborate on IRDs Study
March 26, 2024
Study: Nanodropper Adaptor Matches Traditional Drops in IOP Control

Nanodropper Inc announced that the results from a clinical trial evaluating the Nanodropper® Adaptor...

read more
Study: Nanodropper Adaptor Matches Traditional Drops in IOP Control
March 25, 2024
Lenz Therapeutics Completes Merger with Graphite Bio

Lenz Therapeutics has officially completed its merger with Graphite Bio, paving the way for the newl...

read more
 Lenz Therapeutics Completes Merger with Graphite Bio
March 25, 2024
Nicox Announces Promising Phase 3 Results for Glaucoma Eye Drop

Nicox SA announced the results of its pivotal Mont Blanc Phase 3 trial, which compared the efficacy ...

read more
Nicox Announces Promising Phase 3 Results for Glaucoma Eye Drop
March 21, 2024
Innovent’s Anti-VEGF Drug Achieves Primary Endpoint in Phase 2 Trial for nAMD Treatment

Innovent Biologics announced that its high-dose IBI302 drug has met primary goal in Phase 2 trial fo...

read more
Innovent’s Anti-VEGF Drug Achieves Primary Endpoint in Phase 2 Trial for nAMD Treatment
March 20, 2024
Congress Approves Adjustment to Medicare Physician Payments

On March 8, Congress approved a partial government funding bill that introduces policies to mitigate...

read more
Congress Approves Adjustment to Medicare Physician Payments
March 20, 2024
GRF Announces Record $2.5M Grant for Glaucoma Research

The Glaucoma Research Foundation (GRF) announced an unprecedented $2.5 million allocation in annual ...

read more
GRF Announces Record $2.5M Grant for Glaucoma Research
March 18, 2024
More